The multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and epithelial-mesenchymal transition

Seminars in Cancer Biology

Volumn 29, Issue C, 2014, Pages 51-58

  Klauzinska, Malgorzata ^a   Castro, Nadia P ^a   Rangel, Maria Cristina ^a   Spike, Benjamin T ^b   Gray, Peter C ^c   Bertolette, Daniel ^a   Cuttitta, Frank ^a   Salomon, David ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Cancer; Cripto 1; Epithelial mesenchymal transition; GRP78; Stem cells

Indexed keywords

ALANTOLACTONE; ALK4 PROTEIN; ALK7 PROTEIN; ANTISENSE OLIGONUCLEOTIDE; BETA CATENIN; CRIPTO 1 PROTEIN; EPIDERMAL GROWTH FACTOR; GLUCOSE REGULATED PROTEIN 78; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; GROWTH FACTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE B; PROTEIN NODAL; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TERATOCARCINOMA DERIVED GROWTH FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN; ACTIVIN RECEPTOR 1; ACVR1B PROTEIN, HUMAN; ACVR1C PROTEIN, HUMAN; HEAT SHOCK PROTEIN; MEMBRANE PROTEIN; MOLECULAR CHAPERONE GRP78; SIGNAL PEPTIDE; SMAD2 PROTEIN, HUMAN; TDGF1 PROTEIN, HUMAN; TUMOR PROTEIN;

ANGIOGENESIS; AUTOCRINE EFFECT; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STEM CELL; CANCER THERAPY; CELL INVASION; CELL MEMBRANE; CELL MIGRATION; COLON CANCER; CRIPTO 1 GENE; DRUG TARGETING; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; ENDOSOME; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE FUNCTION; HUMAN; LIPID RAFT; NONHUMAN; PARACRINE SIGNALING; PLURIPOTENT STEM CELL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; CYTOLOGY; GENETICS; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR INVASION; WNT SIGNALING PATHWAY;

ACTIVIN RECEPTORS, TYPE I; BETA CATENIN; CELL MEMBRANE; EPITHELIAL-MESENCHYMAL TRANSITION; GPI-LINKED PROTEINS; HEAT-SHOCK PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, NOTCH; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TGF-BETA SUPERFAMILY PROTEINS; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84927510322     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.08.003     Document Type: Review

References (118)

1. Pierce G.B., Speers W.C. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 1988, 48:1996-2004.
2. Johnston R.N., Pai S.B., Pai R.B. The origin of the cancer cell: oncogeny reverses phylogeny. Biochem Cell Biol 1992, 70:831-834.
3. Dreesen O., Brivanlou A.H. Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 2007, 3:7-17.
4. Abbott D.E., Bailey C.M., Postovit L.M., Seftor E.A., Margaryan N., Seftor R.E., et al. The epigenetic influence of tumor and embryonic microenvironments: how different are they?. Cancer Microenviron 2008, 1:13-21.
5. Bruno R.D., Smith G.H. Reprogramming non-mammary and cancer cells in the developing mouse mammary gland. Semin Cell Dev Biol 2012, 23:591-598.
6. Chen L., Kasai T., Li Y., Sugii Y., Jin G., Okada M., et al. A model of cancer stem cells derived from mouse induced pluripotent stem cells. PLoS ONE 2012, 7:e33544.
7. Nishi M., Sakai Y., Akutsu H., Nagashima Y., Quinn G., Masui S., et al. Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. Oncogene 2014, 33:643-652.
8. Ciccodicola A., Dono R., Obici S., Simeone A., Zollo M., Persico M.G. Molecular characterization of a gene of the 'EGF family' expressed in undifferentiated human NTERA2 teratocarcinoma cells. EMBO J 1989, 8:1987-1991.
9. Dono R., Scalera L., Pacifico F., Acampora D., Persico M.G., Simeone A. The murine cripto gene: expression during mesoderm induction and early heart morphogenesis. Development 1993, 118:1157-1168.
10. Gritsman K., Zhang J., Cheng S., Heckscher E., Talbot W.S., Schier A.F. The EGF-CFC protein one-eyed pinhead is essential for nodal signaling. Cell 1999, 97:121-132.
11. Minchiotti G., Manco G., Parisi S., Lago C.T., Rosa F., Persico M.G. Structure-function analysis of the EGF-CFC family member Cripto identifies residues essential for nodal signalling. Development 2001, 128:4501-4510.
12. Shen M.M., Wang H., Leder P. A differential display strategy identifies Cryptic, a novel EGF-related gene expressed in the axial and lateral mesoderm during mouse gastrulation. Development 1997, 124:429-442.
13. Zhang J., Talbot W.S., Schier A.F. Positional cloning identifies zebrafish one-eyed pinhead as a permissive EGF-related ligand required during gastrulation. Cell 1998, 92:241-251.
14. Watanabe K., Hamada S., Bianco C., Mancino M., Nagaoka T., Gonzales M., et al. Requirement of glycosylphosphatidylinositol anchor of Cripto-1 for trans activity as a Nodal co-receptor. J Biol Chem 2007, 282:35772-35786.
15. Yan Y.T., Liu J.J., Luo Y.E.C, Haltiwanger R.S., Abate-Shen C., et al. Dual roles of Cripto as a ligand and coreceptor in the nodal signaling pathway. Mol Cell Biol 2002, 22:4439-4449.
16. Hamada S., Watanabe K., Hirota M., Bianco C., Strizzi L., Mancino M., et al. beta-Catenin/TCF/LEF regulate expression of the short form human Cripto-1. Biochem Biophys Res Commun 2007, 355:240-244.
17. Mancino M., Strizzi L., Wechselberger C., Watanabe K., Gonzales M., Hamada S., et al. Regulation of human Cripto-1 gene expression by TGF-beta1 and BMP-4 in embryonal and colon cancer cells. J Cell Physiol 2008, 215:192-203.
18. Bianco C., Cotten C., Lonardo E., Strizzi L., Baraty C., Mancino M., et al. Cripto-1 is required for hypoxia to induce cardiac differentiation of mouse embryonic stem cells. Am J Pathol 2009, 175:2146-2158.
19. Morkel M., Huelsken J., Wakamiya M., Ding J., van de Wetering M., Clevers H., et al. Beta-catenin regulates Cripto- and Wnt3-dependent gene expression programs in mouse axis and mesoderm formation. Development 2003, 130:6283-6294.
20. Behrens A.N., Ren Y., Ferdous A., Garry D.J., Martin C.M. Nkx2-5 regulates Tdgf1 (Cripto) early during cardiac development. J Clin Exp Cardiol 2012, Suppl. 11:1-4.
21. Hentschke M., Kurth I., Borgmeyer U., Hubner C.A. Germ cell nuclear factor is a repressor of CRIPTO-1 and CRIPTO-3. J Biol Chem 2006, 281:33497-33504.
22. Bianco C., Castro N.P., Baraty C., Rollman K., Held N., Rangel M.C., et al. Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells. J Cell Physiol 2013, 228:1174-1188.
23. Zhang Y., Forinash K.D., McGivern J., Fritz B., Dorey K., Sheets M.D. Spatially restricted translation of the xCR1 mRNA in Xenopus embryos. Mol Cell Biol 2009, 29:3791-3802.
24. Zhang Y., Park S., Blaser S., Sheets M.D. Determinants of RNA binding and translational repression by the Bicaudal-C regulatory protein. J Biol Chem 2014, 289:7497-7504.
25. Chen F., Hou S.K., Fan H.J., Liu Y.F. MiR-15a-16 represses Cripto and inhibits NSCLC cell progression. Mol Cell Biochem 2014, 391(1-2):11-19.
26. Meno C., Ito Y., Saijoh Y., Matsuda Y., Tashiro K., Kuhara S., et al. Two closely-related left-right asymmetrically expressed genes, lefty-1 and lefty-2: their distinct expression domains, chromosomal linkage and direct neuralizing activity in Xenopus embryos. Genes Cells 1997, 2:513-524.
27. Ding J., Yang L., Yan Y.T., Chen A., Desai N., Wynshaw-Boris A., et al. Cripto is required for correct orientation of the anterior-posterior axis in the mouse embryo. Nature 1998, 395:702-707.
28. Xu C., Liguori G., Persico M.G., Adamson E.D. Abrogation of the Cripto gene in mouse leads to failure of postgastrulation morphogenesis and lack of differentiation of cardiomyocytes. Development 1999, 126:483-494.
29. Wang B., Yan J., Peng Z., Wang J., Liu S., Xie X., et al. Teratocarcinoma-derived growth factor 1 (TDGF1) sequence variants in patients with congenital heart defect. Int J Cardiol 2011, 146:225-227.
30. Bianco C., Rangel M.C., Castro N.P., Nagaoka T., Rollman K., Gonzales M., et al. Role of Cripto-1 in stem cell maintenance and malignant progression. Am J Pathol 2010, 177:532-540.
31. Loh Y.H., Wu Q., Chew J.L., Vega V.B., Zhang W., Chen X., et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 2006, 38:431-440.
32. Vallier L., Mendjan S., Brown S., Chng Z., Teo A., Smithers L.E., et al. Activin/Nodal signalling maintains pluripotency by controlling Nanog expression. Development 2009, 136:1339-1349.
33. Aasen T., Raya A., Barrero M.J., Garreta E., Consiglio A., Gonzalez F., et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 2008, 26:1276-1284.
34. Aoi T., Yae K., Nakagawa M., Ichisaka T., Okita K., Takahashi K., et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 2008, 321:699-702.
35. Boles N.C., Hirsch S.E., Le S., Corneo B., Najm F., Minotti A.P., et al. NPTX1 regulates neural lineage specification from human pluripotent stem cells. Cell Rep 2014, 6:724-736.
36. Liguori G.L., Echevarria D., Bonilla S., D'Andrea D., Liguoro A., Persico M.G., et al. Characterization of the functional properties of the neuroectoderm in mouse Cripto(-/-) embryos showing severe gastrulation defects. Int J Dev Biol 2009, 53:549-557.
37. Miharada K., Karlsson G., Rehn M., Rorby E., Siva K., Cammenga J., et al. Cripto regulates hematopoietic stem cells as a hypoxic-niche-related factor through cell surface receptor GRP78. Cell Stem Cell 2011, 9:330-344.
38. Spike B.T., Kelber J.A., Booker E., Kalathur M., Rodewald R., Lipianskaya J., et al. CRIPTO/GRP78 signaling maintains fetal and adult mammary stem cells ex vivo. Stem Cell Rep 2014, 2:427-439.
39. Bianco C., Strizzi L., Normanno N., Khan N., Salomon D.S. Cripto-1: an oncofetal gene with many faces. Curr Top Dev Biol 2005, 67:85-133.
40. Hirota M., Watanabe K., Hamada S., Sun Y., Strizzi L., Mancino M., et al. Smad2 functions as a co-activator of canonical Wnt/beta-catenin signaling pathway independent of Smad4 through histone acetyltransferase activity of p300. Cell Signal 2008, 20:1632-1641.
41. Nagaoka T., Karasawa H., Turbyville T., Rangel M.C., Castro N.P., Gonzales M., et al. Cripto-1 enhances the canonical Wnt/beta-catenin signaling pathway by binding to LRP5 and LRP6 co-receptors. Cell Signal 2013, 25:178-189.
42. Krebs L.T., Iwai N., Nonaka S., Welsh I.C., Lan Y., Jiang R., et al. Notch signaling regulates left-right asymmetry determination by inducing Nodal expression. Genes Dev 2003, 17:1207-1212.
43. Raya A., Kawakami Y., Rodriguez-Esteban C., Buscher D., Koth C.M., Itoh T., et al. Notch activity induces Nodal expression and mediates the establishment of left-right asymmetry in vertebrate embryos. Genes Dev 2003, 17:1213-1218.
44. Postovit L.M., Seftor E.A., Seftor R.E., Hendrix M.J. Targeting Nodal in malignant melanoma cells. Expert Opin Ther Targets 2007, 11:497-505.
45. Watanabe K., Nagaoka T., Lee J.M., Bianco C., Gonzales M., Castro N.P., et al. Enhancement of Notch receptor maturation and signaling sensitivity by Cripto-1. J Cell Biol 2009, 187:343-353.
46. Harms P.W., Chang C. Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto. Genes Dev 2003, 17:2624-2629.
47. Uchida T., Wada K., Akamatsu T., Yonezawa M., Noguchi H., Mizoguchi A., et al. A novel epidermal growth factor-like molecule containing two follistatin modules stimulates tyrosine phosphorylation of erbB-4 in MKN28 gastric cancer cells. Biochem Biophys Res Commun 1999, 266:593-602.
48. Bianco C., Kannan S., De Santis M., Seno M., Tang C.K., Martinez-Lacaci I., et al. Cripto-1 indirectly stimulates the tyrosine phosphorylation of erb B-4 through a novel receptor. J Biol Chem 1999, 274:8624-8629.
49. Bianco C., Strizzi L., Mancino M., Watanabe K., Gonzales M., Hamada S., et al. Regulation of Cripto-1 signaling and biological activity by caveolin-1 in mammary epithelial cells. Am J Pathol 2008, 172:345-357.
50. Tabibzadeh S., Hemmati-Brivanlou A. Lefty at the crossroads of stemness and differentiative events. Stem Cells 2006, 24:1998-2006.
51. Bendall S.C., Hughes C., Campbell J.L., Stewart M.H., Pittock P., Liu S., et al. An enhanced mass spectrometry approach reveals human embryonic stem cell growth factors in culture. Mol Cell Proteomics 2009, 8:421-432.
52. D'Aniello C., Lonardo E., Iaconis S., Guardiola O., Liguoro A.M., Liguori G.L., et al. G protein-coupled receptor APJ and its ligand apelin act downstream of Cripto to specify embryonic stem cells toward the cardiac lineage through extracellular signal-regulated kinase/p70S6 kinase signaling pathway. Circ Res 2009, 105:231-238.
53. Su D., Jing S., Guan L., Li Q., Zhang H., Gao X., et al. Role of Nodal-PITX2C signaling pathway in glucose-induced cardiomyocyte hypertrophy. Biochem Cell Biol 2014, 92(3):183-190.
54. Gray P.C., Vale W. Cripto/GRP78 modulation of the TGF-beta pathway in development and oncogenesis. FEBS Lett 2012, 586:1836-1845.
55. Shani G., Fischer W.H., Justice N.J., Kelber J.A., Vale W., Gray P.C. GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth. Mol Cell Biol 2008, 28:666-677.
56. Lee A.S. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat Rev Cancer 2014, 14:263-276.
57. Ni M., Zhang Y., Lee A.S. Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J 2011, 434:181-188.
58. Jamora C., Dennert G., Lee A.S. Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. Proc Natl Acad Sci USA 1996, 93:7690-7694.
59. Liu R., Li X., Gao W., Zhou Y., Wey S., Mitra S.K., et al. Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis. Clin Cancer Res 2013, 19:6802-6811.
60. Kelber J.A., Panopoulos A.D., Shani G., Booker E.C., Belmonte J.C., Vale W.W., et al. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways. Oncogene 2009, 28:2324-2336.
61. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
62. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
63. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
64. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
65. Kim C.F., Jackson E.L., Woolfenden A.E., Lawrence S., Babar I., Vogel S., et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005, 121:823-835.
66. Wang X., Kruithof-de Julio M., Economides K.D., Walker D., Yu H., Halili M.V., et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009, 461:495-500.
67. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
68. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
69. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
70. Prince M.E., Sivanandan R., Kaczorowski A., Wolf G.T., Kaplan M.J., Dalerba P., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007, 104:973-978.
71. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
72. Malanchi I., Peinado H., Kassen D., Hussenet T., Metzger D., Chambon P., et al. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 2008, 452:650-653.
73. Kreso A., van Galen P., Pedley N.M., Lima-Fernandes E., Frelin C., Davis T., et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med 2014, 20:29-36.
74. Micalizzi D.S., Farabaugh S.M., Ford H.L. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010, 15:117-134.
75. Oskarsson T., Batlle E., Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 2014, 14:306-321.
76. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008, 40:499-507.
77. Spike B.T., Engle D.D., Lin J.C., Cheung S.K., La J., Wahl G.M. A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer. Cell Stem Cell 2012, 10:183-197.
78. Youssef K.K., Lapouge G., Bouvree K., Rorive S., Brohee S., Appelstein O., et al. Adult interfollicular tumour-initiating cells are reprogrammed into an embryonic hair follicle progenitor-like fate during basal cell carcinoma initiation. Nat Cell Biol 2012, 14:1282-1294.
79. Chang H.Y., Sneddon J.B., Alizadeh A.A., Sood R., West R.B., Montgomery K., et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004, 2:E7.
80. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
81. Scheel C., Weinberg R.A. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Sem Cancer Biol 2012, 22:396-403.
82. Meacham C.E., Morrison S.J. Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501:328-337.
83. Spike B.T., Wahl G.M. p53, stem cells, and reprogramming: tumor suppression beyond guarding the genome. Genes Cancer 2011, 2:404-419.
84. de Castro N.P., Rangel M.C., Nagaoka T., Salomon D.S., Bianco C. Cripto-1: an embryonic gene that promotes tumorigenesis. Future Oncol 2010, 6:1127-1142.
85. Strizzi L., Abbott D.E., Salomon D.S., Hendrix M.J. Potential for Cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle 2008, 7:1931-1935.
86. Strizzi L., Bianco C., Normanno N., Seno M., Wechselberger C., Wallace-Jones B., et al. Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol 2004, 201:266-276.
87. Wechselberger C., Ebert A.D., Bianco C., Khan N.I., Sun Y., Wallace-Jones B., et al. Cripto-1 enhances migration and branching morphogenesis of mouse mammary epithelial cells. Exp Cell Res 2001, 266:95-105.
88. Wechselberger C., Strizzi L., Kenney N., Hirota M., Sun Y., Ebert A., et al. Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. Oncogene 2005, 24:4094-4105.
89. di Bari M.G., Ginsburg E., Plant J., Strizzi L., Salomon D.S., Vonderhaar B.K. Msx2 induces epithelial-mesenchymal transition in mouse mammary epithelial cells through upregulation of Cripto-1. J Cell Physiol 2009, 219:659-666.
90. Micalizzi D.S., Wang C.A., Farabaugh S.M., Schiemann W.P., Ford H.L. Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. Cancer Res 2010, 70:10371-10380.
91. Watanabe K., Meyer M.J., Strizzi L., Lee J.M., Gonzales M., Bianco C., et al. Cripto-1 is a cell surface marker for a tumorigenic, undifferentiated subpopulation in human embryonal carcinoma cells. Stem Cells 2010, 28:1303-1314.
92. Lonardo E., Hermann P.C., Mueller M.T., Huber S., Balic A., Miranda-Lorenzo I., et al. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011, 9:433-446.
93. Cocciadiferro L., Miceli V., Kang K.S., Polito L.M., Trosko J.E., Carruba G. Profiling cancer stem cells in androgen-responsive and refractory human prostate tumor cell lines. Ann N Y Acad Sci 2009, 1155:257-262.
94. Scheel C., Eaton E.N., Li S.H., Chaffer C.L., Reinhardt F., Kah K.J., et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145:926-940.
95. Nagaoka T., Karasawa H., Castro N.P., Rangel M.C., Salomon D.S., Bianco C. An evolving web of signaling networks regulated by Cripto-1. Growth Factors 2012, 30:13-21.
96. Rangel M.C., Karasawa H., Castro N.P., Nagaoka T., Salomon D.S., Bianco C. Role of Cripto-1 during epithelial-to-mesenchymal transition in development and cancer. Am J Pathol 2012, 180:2188-2200.
97. Liu X., Lee J., Cooley M., Bhogte E., Hartley S., Glick A. Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma. Cancer Res 2003, 63:7760-7768.
98. Bianco C., Strizzi L., Ebert A., Chang C., Rehman A., Normanno N., et al. Role of human Cripto-1 in tumor angiogenesis. J Natl Cancer Inst 2005, 97:132-141.
99. Kenney N.J., Smith G.H., Maroulakou I.G., Green J.H., Muller W.J., Callahan R., et al. Detection of amphiregulin and Cripto-1 in mammary tumors from transgenic mice. Mol Carcinog 1996, 15:44-56.
100. Sun Y., Strizzi L., Raafat A., Hirota M., Bianco C., Feigenbaum L., et al. Overexpression of human Cripto-1 in transgenic mice delays mammary gland development and differentiation and induces mammary tumorigenesis. Am J Pathol 2005, 167:585-597.
101. Strizzi L., Bianco C., Hirota M., Watanabe K., Mancino M., Hamada S., et al. Development of leiomyosarcoma of the uterus in MMTV-CR-1 transgenic mice. J Pathol 2007, 211:36-44.
102. Bianco C., Strizzi L., Mancino M., Rehman A., Hamada S., Watanabe K., et al. Identification of Cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res 2006, 12:5158-5164.
103. Tysnes B.B., Satran H.A., Mork S.J., Margaryan N.V., Eide G.E., Petersen K., et al. Age-dependent association between protein expression of the embryonic stem cell marker Cripto-1 and survival of glioblastoma patients. Transl Oncol 2013, 6:732-741.
104. Pilgaard L., Mortensen J.H., Henriksen M., Olesen P., Sorensen P., Laursen R., et al. Cripto-1 expression in glioblastoma multiforme. Brain Pathol 2014, 24(4):360-370.
105. Sell S. Cancer and stem cell signaling: a guide to preventive and therapeutic strategies for cancer stem cells. Stem Cell Rev 2007, 3:1-6.
106. De Luca A., Casamassimi A., Selvam M.P., Losito S., Ciardiello F., Agrawal S., et al. EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. Int J Cancer 1999, 80:589-594.
107. De Luca A., Arra C., D'Antonio A., Casamassimi A., Losito S., Ferraro P., et al. Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. Oncogene 2000, 19:5863-5871.
108. Casamassimi A., De Luca A., Agrawal S., Stromberg K., Salomon D.S., Normanno N. EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells. Ann Oncol 2000, 11:319-325.
109. Normanno N., De Luca A., Maiello M.R., Bianco C., Mancino M., Strizzi L., et al. CRIPTO-1: a novel target for therapeutic intervention in human carcinoma. Int J Oncol 2004, 25:1013-1020.
110. Adkins H.B., Bianco C., Schiffer S.G., Rayhorn P., Zafari M., Cheung A.E., et al. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Investig 2003, 112:575-587.
111. Biogen-Idec A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors 2011.
112. Xing P.X., Hu X.F., Pietersz G.A., Hosick H.L., McKenzie I.F. Cripto: a novel target for antibody-based cancer immunotherapy. Cancer Res 2004, 64:4018-4023. http://clinicaltrials.gov.
113. Hu X.F., Li J., Yang E., Vandervalk S., Xing P.X. Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways. Br J Cancer 2007, 96:918-927.
114. Bianco C., Salomon D.S. Targeting the embryonic gene Cripto-1 in cancer and beyond. Expert Opin Ther Patents 2010, 20:1739-1749.
115. Kelly R.K., Olson D.L., Sun Y., Wen D., Wortham K.A., Antognetti G., et al. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours. Eur J Cancer 2011, 47:1736-1746.
116. Rasul A., Khan M., Ali M., Li J., Li X. Targeting apoptosis pathways in cancer with alantolactone and isoalantolactone. ScientificWorldJournal 2013, 2013:248532.
117. Shi Y., Bao Y.L., Wu Y., Yu C.L., Huang Y.X., Sun Y., et al. Alantolactone inhibits cell proliferation by interrupting the interaction between Cripto-1 and activin receptor type II A in activin signaling pathway. J Biomol Screen 2011, 16:525-535.
118. Lonardo E., Parish C.L., Ponticelli S., Marasco D., Ribeiro D., Ruvo M., et al. A small synthetic cripto blocking Peptide improves neural induction, dopaminergic differentiation, and functional integration of mouse embryonic stem cells in a rat model of Parkinson's disease. Stem Cells 2010, 28:1326-1337.